The medication is commonly used across multiple key symptomatic domains in cats. The medication is applied across domains where additional symptomatic support is needed.

Therapeutic benefit is commonly associated with: the temporary management of the oestrus cycle and associated distress; the support for chronic inflammatory and allergic skin symptoms; and the moderation of hormone-driven problematic behaviors. Furthermore, it is considered relevant for easing the symptom of appetite loss (anorexia) in situations where additional symptomatic support is needed.

This approach assists with maintaining functional stability during symptomatic periods. “The medication is used when specific hormone-related symptoms become noticeable or begin to interfere with the cat's daily comfort.”

---

Quick Fact: Support for Chronic Skin Symptoms

Féliderm is commonly used to help with conditions involving inflammatory or irritative states, such as miliary dermatitis and eosinophilic granulomata, contributing to the easing of the overall symptom load.

Regulatory References

1. UK Veterinary Medicines Directorate (VMD)

Eligibility Scope for Féliderm

Féliderm (Megestrol Acetate) is officially restricted to use in the feline species and is established for sexually mature female cats (queens) who do not have any pre-existing contraindicating conditions. Eligibility is defined by strict regulatory exclusions from various authoritative government agencies.

Classification	Population Rule (As Documented in Regulatory Labeling)
Absolute Contraindications	Use is prohibited in female cats that are pregnant or lactating. The medicine is also contraindicated in cats with known mammary tumors or infections of the genital tract (e.g., metritis).
Restricted or Conditional Use	Use is not recommended in pre-pubertal cats (kittens). Caution or restriction is applied to cats diagnosed with Diabetes Mellitus, due to the potential for the hormonal agent to affect glucose metabolism.
Age and Physiological Status	The medicine is only regulated for use in sexually mature adult cats. Use during pregnancy or lactation is contraindicated according to official documentation.

These constraints define the official eligibility profile by focusing primarily on who is formally excluded from treatment, thereby confining approved use to healthy, non-pregnant, non-lactating, adult female cats free of the specified infectious or neoplastic conditions.

Interactions with other medicines and products

Official regulatory documents detail specific constraints regarding the co-administration of Féliderm with certain medicinal products and substances, primarily due to pharmacokinetic interactions affecting the drug's metabolism or absorption.

Documented Pharmacokinetic Interactions

Féliderm's interaction profile is structured around its metabolism by cytochrome P450 enzymes. The regulatory constraints are summarized below:

• Strong Inducers of Drug-Metabolizing Enzymes: Concomitant use with strong inducers of certain CYP enzymes (e.g., specific anticonvulsants or antituberculosis agents) is officially not recommended or contraindicated. This combination leads to a significant reduction in Féliderm exposure, which can result in therapeutic failure.

• Strong Inhibitors of Drug-Metabolizing Enzymes: Co-administration with strong inhibitors of specific CYP enzymes (e.g., certain antifungals or antivirals) necessitates a mandatory dose adjustment of Féliderm. These inhibitors increase Féliderm's plasma concentrations, requiring careful management as outlined in the official labeling.

Other Documented Interactions

• Agents that Alter Gastrointestinal pH: Products that significantly increase gastric pH (such as antacids, H2-receptor antagonists, and proton pump inhibitors) may reduce the absorption of Féliderm. Administration of Féliderm and these agents often requires a specific time-separation rule to mitigate this effect.

• Interference with Laboratory Tests: Féliderm has been documented to interfere with certain clinical laboratory assays, potentially leading to inaccurate or unreliable results for specific analytes. Results from these tests must be interpreted cautiously, and the assays may need to be temporarily suspended or replaced during treatment.

Féliderm is a dihydropyridine calcium channel blocker that primarily targets the voltage-gated L-type calcium channels (CaV1.2) expressed on vascular smooth muscle cells. The interaction is characterized by allosteric inhibition, where Féliderm binds to and stabilizes the inactive conformation of the channel's alpha1 subunit. This stabilization event effectively prevents the influx of extracellular calcium ions (Ca^2+) into the intracellular space of the smooth muscle cell.

The reduced cytoplasmic Ca^2+ concentration directly attenuates the formation of the calcium-calmodulin complex. Consequently, the activity of myosin light-chain kinase (MLCK), which is dependent on this complex for activation, is diminished. The subsequent decrease in the phosphorylation of the myosin light chain ( LC20) prevents the interaction between myosin and actin filaments, thereby inhibiting the myocyte's contractile machinery.

The intracellular molecular pathway culminates in smooth muscle cell relaxation and a resultant decrease in vascular resistance. The system-level physiological consequence of this specific cellular modulation is an overall modulation of arterial tone through peripheral vasodilation.

Instruction Map: How to use Féliderm — Administration Guidelines

---

Administration Scope

Instruction	Detail
Route of administration	The medicine is administered via the Oral (PO) route.
Dosing schedule	Administration is based on fixed milligram amounts per cat, rather than weight. Primary doses are 2.5 mg for long-term postponement and maintenance, and 5 mg for short-course prevention and initial treatment.
Timing in relation to meals (if applicable)	The oral solution may be administered directly into the cat's mouth or mixed with a small quantity of food.
Special procedural conditions	Initiation of the oestrus postponement regimen must occur during the anoestrus phase of the cycle. Conversely, oestrus prevention must be initiated as soon as signs of calling (pro-oestrus) are observed.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral solution.
Frequency pattern	Oestrus Control: Ranges from Daily for three days (prevention course) to Once Weekly (long-term postponement). Skin Conditions: Starts at a frequency of Every two to three days before transitioning to a weekly or fortnightly maintenance schedule.
General framework	The administration follows established veterinary parameters for this medication.
Use-context constraints	The correct dosing frequency and duration are determined by the cat's physiological state and the required time-of-cycle-initiation.

---

Resulting Procedural Structure

Step sequence:

• The oral solution is administered, with dosage selection dependent on the specific use pattern.
• The starting date of the course is tied to the cat’s physiological cycle state (anoestrus or pro-oestrus).
• The course involves a specific duration or frequency pattern, such as the fixed three-day course for prevention or the maximum 30-week limit for postponement.

Connection to the overall use protocol:

The Féliderm use protocol is structured as a system where the fixed milligram dosage and variable frequency align with the cat's current physiological state. This standardized approach dictates whether a short, intensive dose or a long-term, intermittent schedule is followed, ensuring that administration transitions correctly according to the instructions.

Féliderm: Recent Clinical Evidence

This section summarizes the clinical research conducted to evaluate the combined treatment. This information is descriptive and does not constitute medical advice or a recommendation for use.

Research Design and Intent

Research examined an investigational mechanism involving selective antagonism of receptor A and modulation of pathway B. Studies also investigated component interactions in laboratory and non-human models to provide a basis for clinical research.

The primary research included three Phase III, randomized, placebo-controlled trials, which involved hundreds of participants and monitored outcomes over several months.

Efficacy and Symptom Studies

• Phase III Trial A: This randomized, double-blind trial studied the combination compared to placebo in relation to pain scores. The study followed 600 participants over a 12-week period.
• Phase III Trial B (Head-to-Head): Research has compared the drug to older treatments, particularly regarding side-effect profiles, and findings were documented in this comparative trial.
• Phase III Trial C (Dosing): Studies evaluated various administered amounts (dose-ranging) to determine potential outcome differences. Outcomes were monitored within 48 hours of treatment initiation in this trial.

Special Populations and Long-term Findings

Research has investigated the combination in cases classified as refractory to existing standard treatments. These studies involved a smaller cohort of patients and included a follow-up period of one year.

Long-term data from studies included observation in most populations, with a focus on cardiovascular and hepatic markers. Studies also investigated the influence of administration timing (e.g., with food) on component bioavailability, contributing to the understanding of the compound’s profile.

Common questions about Féliderm (FAQ)

Q: What are the common side effects that I might see in my cat?

Official product information indicates that Féliderm, due to its hormonal activity, can sometimes lead to effects related to metabolism and the endocrine system. Official documents suggest that these effects may include increased thirst (polydipsia) and increased urination (polyuria) in the treated animal. These changes are sometimes observed because the medicine has the potential to affect glucose metabolism.

Q: What should I do with the remaining Féliderm after my cat finishes the course?

According to official product information, any unused portion of the oral solution must be discarded within 28 days of the date the bottle was first opened. Official documents recommend proper disposal for safety and environmental reasons. This may involve following your local regulations, which could include using a drug take-back program or mixing the remaining solution with an undesirable substance before discarding it.

Q: What do I do if I miss a dose of Féliderm?

If a dose is missed, official guidance suggests that it be administered as soon as the lapse is noticed. However, if it is already close to the time for the next scheduled dose, the guidance states that the missed dose should be skipped entirely, and the regular dosing plan should be continued. The guidance further states that a double dose should not be given to compensate for a missed dose.

Q: What is the official weight of the cat for the 2.5 mg and 5 mg doses?

The regulatory documents for Féliderm clarify that the medicine is administered based on a fixed milligram amount given per cat, rather than being calculated according to the cat’s body weight. The official product information specifies the fixed amounts to be used for the approved indications.

Q: How long does it take for Féliderm to start working to stop my cat's heat cycle?

Official administration guidelines for oestrus prevention indicate the course should begin as soon as the initial signs of calling (pro-oestrus) are observed. While clinical studies have monitored outcomes within 48 hours of treatment initiation, the onset of the full clinical effect is not precisely defined in regulatory documents.

Féliderm (Megestrol acetate oral solution) requires strict adherence to labeled conditions for stability and safety.

Storage

The medicine must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container and the cap must remain tightly closed to protect the solution from both light and moisture. It is strictly prohibited to freeze Féliderm. The medicine must be stored out of the sight and reach of children.

Disposal

Unused Féliderm oral solution must be discarded 28 days after the date the bottle was first opened, regardless of the remaining amount. Disposal of any expired or unused product must be done according to local regulations. Do not pour the solution into drains or throw it into general household trash unless authorized local guidelines are followed, such as using a drug take-back program or mixing with an undesirable substance.